Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Shanghai Pharmaceuticals Holding Co., Ltd (601607.SS)

Compare
18.64
-0.06
(-0.32%)
At close: 3:00:03 PM GMT+8
Currency in CNY All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
275,250,934.89
275,250,934.89
260,295,088.94
231,981,299.76
215,824,259.04
Cost of Revenue
244,619,261.05
244,619,261.05
228,966,947
201,494,923.09
187,281,149.28
Gross Profit
30,631,673.84
30,631,673.84
31,328,141.94
30,486,376.68
28,543,109.75
Operating Expense
20,941,761.56
20,941,761.56
21,762,997.48
21,705,375.12
20,616,170.64
Operating Income
9,689,912.28
9,689,912.28
9,565,144.47
8,781,001.55
7,926,939.11
Net Non Operating Interest Income Expense
-1,480,912.18
-1,480,912.18
-1,275,734.91
-1,057,100.63
-1,368.08
Pretax Income
8,020,006.54
8,020,006.54
7,054,296.74
8,808,353.28
8,143,814.89
Tax Provision
2,149,995.23
2,149,995.23
1,887,726.45
1,816,338.51
1,869,245.45
Net Income Common Stockholders
4,552,528.44
4,552,528.44
3,767,999.58
5,617,152
5,093,467.26
Basic EPS
1.23
--
1.02
1.61
1.79
Diluted EPS
1.23
--
1.02
1.61
1.79
Basic Average Shares
3,701,242.63
--
3,694,117.24
3,488,914.29
2,845,512.44
Diluted Average Shares
3,701,242.63
--
3,694,117.24
3,488,914.29
2,845,512.44
Total Operating Income as Reported
8,140,712.95
8,140,712.95
7,667,234.70
9,014,650.39
8,205,486.31
Rent Expense Supplemental
225,264.32
225,264.32
259,575.83
261,645.83
269,350.74
Total Expenses
265,561,022.61
265,561,022.61
250,729,944.48
223,200,298.21
207,897,319.93
Net Income from Continuing & Discontinued Operation
4,552,528.44
4,552,528.44
3,767,999.58
5,617,152
5,093,467.26
Normalized Income
4,997,122.93
4,997,122.93
4,157,364.12
4,876,371.06
5,375,221.39
Interest Income
522,385.72
522,385.72
461,833.29
438,297.67
338,179.84
Interest Expense
1,856,737.43
1,856,737.43
1,663,554.79
1,411,675.94
264,131.58
Net Interest Income
-1,480,912.18
-1,480,912.18
-1,275,734.91
-1,057,100.63
-1,368.08
EBIT
9,876,743.97
9,876,743.97
8,717,851.53
10,220,029.22
8,407,946.47
EBITDA
12,295,542.75
12,295,542.75
10,904,982.35
12,442,470.08
10,547,750.84
Reconciled Cost of Revenue
244,619,261.05
244,619,261.05
228,966,947
201,494,923.09
187,281,149.28
Reconciled Depreciation
2,418,798.78
2,418,798.78
2,187,130.82
2,222,440.86
2,139,804.37
Net Income from Continuing Operation Net Minority Interest
4,552,528.44
4,552,528.44
3,767,999.58
5,617,152
5,093,467.26
Total Unusual Items Excluding Goodwill
-607,435.07
-607,435.07
-531,627.92
933,216.03
-365,690.99
Total Unusual Items
-607,435.07
-607,435.07
-531,627.92
933,216.03
-365,690.99
Normalized EBITDA
12,902,977.83
12,902,977.83
11,436,610.27
11,509,254.05
10,913,441.82
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-162,840.58
-162,840.58
-142,263.38
192,435.09
-83,936.86
12/31/2021 - 3/24/1994

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade